Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | RXRG | P48443 | 2/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892518 | 0.92 | FFAR1 (0.47) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL1894408 | 0.89 | FFAR1 (0.50) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL16605163 | 0.84 | FFAR1 (0.50) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL16605158 | 0.84 | FFAR1 (0.54) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL15948945 | 0.82 | FFAR1 (0.48) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL1891473 | 0.80 | CYP4F2 (0.39) | FFAR1FFAR4AKR1C3AKR1C2CNR2 | |
| SCHEMBL35843123 | 0.80 | CYP4F2 (0.39) | FFAR1FFAR4AKR1C3AKR1C2CNR2 | |
| SCHEMBL1802536 | 0.80 | FFAR1 (0.48) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL38660342 | 0.80 | FFAR1 (0.48) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL35843129 | 0.78 | MTNR1A (0.44) | FFAR1FFAR4AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204197-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | FIBROSTATIN S L (ES) | 2017-07-20 | — | — | US | disclosed |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | FIBROSTATIN, S.L. (ES) | 2015-11-12 | — | — | US | disclosed |
| US-9066938-B2 | GPBP-1 inhibition and its therapeutic use | Fibrostein, S.L. (ES) | 2015-06-30 | — | — | US | disclosed |
| US-20150093378-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | FIBROSTATIN, S.L. (ES) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204197-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | CD2BP2, SAP30BP, LY96 | FFAR1 3034/4885FFAR4 2309/4885PTGER4 2192/4885 |
| US-20150093378-A1 | Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes | CD2BP2, SAP30BP, LY96 | FFAR1 3034/4885FFAR4 2309/4885PTGER4 2192/4885 |
| US-20150320730-A1 | GPBP-1 inhibition and its therapeutic use | ABCC1, ABCC8, ABCB1 | FFAR1 2553/4885FFAR4 3802/4885PTGER4 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.